Form 4: Amylyx CLO Sells Shares for Tax Obligations

Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, sold 6,844 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported a sale of common stock.
• The transaction involved the disposition of 6,844 shares of common stock on March 2, 2026.
• The shares were sold at a weighted average price of $14.5205 per share, with individual sales ranging from $14.400 to $15.070.
• The sale was automatic and not at the discretion of Ms. Mazzariello, executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Ms. Mazzariello directly beneficially owns 134,430 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a standard, non-discretionary sale to cover tax obligations from RSU vesting, which is a common occurrence for executives.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions. Sales to cover tax withholding obligations upon RSU vesting are common and generally not indicative of management's sentiment towards the company's future prospects, but rather a standard compensation and tax event.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not a discretionary sale indicating a change in insider sentiment.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a Chief Legal Officer to cover tax obligations arising from restricted stock unit vesting. Such transactions are common and typically do not reflect a change in the insider's view of the company's fundamentals or future prospects. Therefore, it provides no new information that would warrant a change in investment recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Amylyx Pharmaceuticals, AMLX, Insider Trading, Form 4, Stock Sale, Chief Legal Officer, Gina Mazzariello, Restricted Stock Units, Tax Withholding